|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS11854 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-TSFP1/SP1 |
| 克隆性 | |
| 靶點 | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human TSFP1/SP1 |
產(chǎn)品訂購信息：
英文名稱 Anti-TSFP1/SP1
中文名稱 轉(zhuǎn)錄生長因子SP1抗體規(guī)格
別 名 Sp1 transcription factor isoform a; TSFP1; TSFP 1; Specificity protein 1; Transcription factor Sp1; SP1_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 發(fā)育生物學(xué) 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 干細(xì)胞 生長因子和激素 轉(zhuǎn)錄調(diào)節(jié)因子 鋅指蛋白 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 81kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human TSFP1/SP1
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
轉(zhuǎn)錄生長因子SP1抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Profound changes in patterns of gene expression can result from relatively small changes in the concentrations of sequence specific transcription factors. Synergistic interaction between factors bound to different sites within a transcriptional control region is supported by the work of Courey et al. (1989). Sp1 is a sequence specific transcription factor that recognizes GGGGCGGGGC and closely related sequences, which are often referred to as GC boxes. Sp1 binds to GC box promoters elements and selectively activates mRNA synthesis from genes that contain functional recognition sites. SP1 can interact with G/C rich motifs from serotonin receptor promoter. Kadonaga et al. (1987) cloned the human Sp1 cDNA and showed that it has contiguous zinc finger motifs and requires zinc for sequence specific binding to DNA. Altername：Sp1 transcription factor isoform a; TSFP1; TSFP 1; Specificity protein 1; Transcription factor Sp1.
Function : Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Binds also the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression.
Subcellular Location : Nucleus. Cytoplasm. Nuclear location is governed by glycosylated/phosphorylated states. Insulin promotes nuclear location, while glucagon favors cytoplasmic location.
Tissue Specificity : Up-regulated in adenocarcinomas of the stomach (at protein level).
Post-translational modifications : Phosphorylated on multiple serine and threonine residues. Phosphorylation is coupled to ubiquitination, sumoylation and proteolytic processing. Phosphorylation on Ser-59 enhances proteolytic cleavage. Phosphorylation on Ser-7 enhances ubiquitination and protein degradation. Hyperphosphorylation on Ser-101 in response to DNA damage has no effect on transcriptional activity. MAPK1/MAPK3-mediated phosphorylation on Thr-453 and Thr-739 enhances VEGF transcription but, represses FGF2-triggered PDGFR-alpha transcription. Also implicated in the repression of RECK by ERBB2. Hyperphosphorylated on Thr-278 and Thr-739 during mitosis by MAPK8 shielding SP1 from degradation by the ubiquitin-dependent pathway. Phosphorylated in the zinc-finger domain by calmodulin-activated PKCzeta. Phosphorylation on Ser-641 by PKCzeta is critical for TSA-activated LHR gene expression through release of its repressor, p107.
Phosphorylation on Thr-668, Ser-670 and Thr-681 is stimulated by angiotensin II via the AT1 receptor inducing increased binding to the PDGF-D promoter. This phosphorylation is increased in injured artey wall. Ser-59 and Thr-681 can both be dephosphorylated by PP2A during cell-cycle interphase. Dephosphorylation on Ser-59 leads to increased chromatin association during interphase and increases the transcriptional activity. On insulin stimulation, sequentially glycosylated and phosphorylated on several C-terminal serine and threonine residues.
Acetylated. Acetylation/deacetylation events affect transcriptional activity. Deacetylation leads to an increase in the expression the 12(s)-lipooxygenase gene though recruitment of p300 to the promoter.
Ubiquitinated. Ubiquitination occurs on the C-terminal proteolytically-cleaved peptide and is triggered by phosphorylation.
Sumoylated by SUMO1. Sumoylation modulates proteolytic cleavage of the N-terminal repressor domain. Sumoylation levels are attenuated during tumorigenesis. Phosphorylation mediates SP1 desumoylation.
Proteolytic cleavage in the N-terminal repressor domain is prevented by sumoylation. The C-terminal cleaved product is susceptible to degradation. O-glycosylated; contains at least 8 N-acetylglucosamine
side chains. Levels are controlled by insulin and the SP1 phosphorylation states. Insulin-mediated O-glycosylation locates SP1 to the nucleus, where it is sequentially deglycosylated and phosphorylated. O-glycosylation affects transcriptional activity through disrupting the interaction with a number of transcription factors including ELF1 and NFYA. Also inhibits interaction with the 1 promoter. Inhibited by peroxisomome proliferator receptor gamma (PPARgamma).
Similarity : Belongs to the Sp1 C2H2-type zinc-finger protein family.
Contains 3 C2H2-type zinc fingers.
Database links :
UniProtKB/Swiss-Prot: P08047.3
Entrez Gene: 395303 Chicken
Entrez Gene: 540741 Cow
Entrez Gene: 6667 Human
Entrez Gene: 20683 Mouse
Entrez Gene: 397314 Pig
Entrez Gene: 24790 Rat
OAT4L又稱URAT1 (Urate Transporter 1) 尿酸鹽重吸收轉(zhuǎn)運(yùn)子1 (抗原)Multi-class antibodies規(guī)格： 0.5mg
Anti-CD328/Siglec-7 唾液酸結(jié)合性免疫球蛋白樣凝集素7抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh ORAV1 高表達(dá)的蛋白1抗體 規(guī)格 0.2ml
CIB2 Kit Human 人 CIB2 ELISA配對抗體 ELISA
TRIP 英文名稱： 壞死因子受體相互作用蛋白抗體 0.1ml
CaIPLA2 英文名稱： 胞漿鈣獨(dú)立磷脂酶A2抗體 0.1ml
Anti-CD328/Siglec-7 唾液酸結(jié)合性免疫球蛋白樣凝集素7抗體Multi-class antibodies規(guī)格： 0.2ml
OCLN(Occluding) 咬合蛋白抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-Aromatase 芳香化酶/細(xì)胞色素P450/雌激素合成酶抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh phospho-ATF2 (Thr51) 磷酸化活化復(fù)制因子2抗體 規(guī)格 0.1ml
Vimentin 波形蛋白 濃縮液 0.1ml 進(jìn)口分裝
UTF1 英文名稱： 未分化胚胎干細(xì)胞轉(zhuǎn)錄因子1抗體 0.2ml
DOCK3 英文名稱： 視神經(jīng)細(xì)胞相關(guān)蛋白/早老素結(jié)合蛋白抗體 0.2ml
Anti-Aromatase 芳香化酶/細(xì)胞色素P450/雌激素合成酶抗體Multi-class antibodies規(guī)格： 0.1ml
Anti-TIGAR humen/FITC 熒光素標(biāo)記兔抗人TIGAR蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
B7-H1/PDL1/CD274(programmed death ligand 1) 程序性死亡配體1(多肽)Multi-class antibodies規(guī)格： 0.5mg
生長抑素受體5抗體 Anti-SSTR5 0.2ml
S100P 英文名稱： S100鈣結(jié)合蛋白P抗體 0.1ml
ET-1 英文名稱： 內(nèi)皮素-1抗體 0.1ml
Rhesus antibody Rh Phospho-MAP2(Ser136) 磷酸化微管相關(guān)蛋白2抗體 規(guī)格 0.1ml
B7-H1/PDL1/CD274(programmed death ligand 1) 程序性死亡配體1(多肽)Multi-class antibodies規(guī)格： 0.5mg
大鼠內(nèi)皮型合成酶3(eNOS-3)ELISA試劑盒 ，英文名： eNOS-3 ELISA Kit
人CXC趨化因子配體16(CXCL16)ELISA檢測試劑盒HumanCXC-chemokineligand16,CXCL16ELISAKit 96T/48T
魚白介素6(IL-6)免疫試劑盒 Fish Ierleukin 6,IL-6 ELISA Kit
CLIAKitforPC/CPGELISAKit小鼠膽堿磷酸甘油酯規(guī)格：48T/96T
雙參數(shù)細(xì)胞周期G1期流式細(xì)胞分析試劑盒10次
ELISAKitHCV-IgG人型肝炎IgG規(guī)格：48T/96T
大鼠成纖維細(xì)胞生長因子9(FGF9)ELISA試劑盒 ，英文名： FGF9 ELISA Kit
Mouse 8 ISO prostaglandin (8-iso-PG) ELISA Kit 小鼠8異素(8-iso-PG)ELISA試劑盒
ELISA 小鼠sCD40配體(mouse sCD40 Ligand) 48T/96T 進(jìn)口分裝
CLIAKitforLEP(HumanLeptin)ELISAkit人瘦素規(guī)格：48T/96T
通用型HRP-DAB底物顯色試劑盒10次
ELISAKitLTC4猴子白三烯C4規(guī)格：48T/96T
轉(zhuǎn)錄生長因子SP1抗體規(guī)格 大鼠多功能肽酶2(LMP2)ELISA試劑盒 ，英文名： LMP2 ELISA Kit
Rat ierleukin 13 (IL-13) ELISA Kit 大鼠白介素13(IL-13)ELISA試劑盒
RatSolubleClusterofdiffereiation30ligand,sCD30LELISAKit 大鼠可溶性白細(xì)胞分化抗原30配體(sCD30L)ELISA試劑盒 96T/48T 進(jìn)口分裝
CLIAKitforDAO(Ratdiamineoxidase,DAO)ELISAKit大鼠氧化酶規(guī)格：48T/96T
細(xì)胞色素C蛋白免疫共沉淀分析試劑盒5次
RatGlycatedhemoglobinA1c,A1cELISAKit大鼠A1c(A1c)ELISA試劑盒規(guī)格：96T/48T
抗體的生物素化標(biāo)記實驗要點：
1. 轉(zhuǎn)錄生長因子SP1抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）轉(zhuǎn)錄生長因子SP1抗體規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
|
|
|
|
|
